サマリー

市場分析と洞察。世界のドラッグ・デバイス併用製品市場
この調査レポートでは、市場に関する正確で詳細な情報を提供するために、さまざまな方法論と分析を用いてドラッグ・デバイス併用製品市場を調査しています。より明確な理解のために、市場のさまざまな側面をカバーするためにいくつかのパートに分かれています。そして、各地域の成長の可能性と世界市場への貢献度を読者が理解できるように、各分野を詳しく説明しています。研究者は、一次および二次の方法論を用いて本レポートの情報を収集しました。また、同じデータを用いて現在の市場シナリオを作成しました。本報告書は、市場に対する不安、より良い、より明確な知識へと導くことを目的としています。
ドラッグ・デバイス併用製品の世界市場規模は、2020年の76220百万米ドルから、2021-2027年の間に6.24%のCAGRで、2027年には117202百万米ドルに達すると予測しています。
世界のドラッグ・デバイス併用製品のスコープとセグメント
世界のドラッグ・デバイス併用製品市場は、企業別、地域（国）別、タイプ別、アプリケーション別に分類されています。世界のドラッグ・デバイス併用製品市場のプレイヤー、ステークホルダー、その他の参加者は、本レポートを強力なリソースとして活用することで、優位に立つことができるでしょう。セグメント別分析では、2016年から2027年までの地域（国）別、タイプ別、アプリケーション別の収益と予測に焦点を当てています。
企業別
GSK
ノボ ノルディスク
Eli Lilly
アストラゼネカ
サノフィ
ボストン・サイエンティフィック
アボット
ベーリンガーインゲルハイム（Boehringer Ingelheim
メドトロニック
マイラン
3M
久光製薬
スミス＆ネフュー
モルンリーケ
テレフレックス
BD
レプ・メディカル
マイクロポート
テルモ
ビー・ブラウン
アンタレス・ファーマ

タイプ別セグメント
薬剤封入デバイス
プレフィルドドラッグデリバリーシステム
ネブライザー＆インヘラー
経皮吸収型製剤
その他

用途別セグメント
病院・診療所
小売薬局
その他

地域別
北アメリカ
アメリカ
カナダ
メキシコ

アジア太平洋
中国
日本
韓国
東南アジア
インド
オーストラリア

ヨーロッパ
ドイツ
フランス
U.K.
イタリア
ロシア

南米
ブラジル

中近東・アフリカ
中近東
アフリカ

ページTOPに戻る

目次

1 MARKET OVERVIEW OF DRUG-DEVICE COMBINATION PRODUCTS 1
1.1 Drug-Device Combination Products Market Overview 1
1.1.1 Drug-Device Combination Products Product Scope 1
1.1.2 Drug-Device Combination Products Market Status and Outlook 2
1.2 Drug-Device Combination Products Market Overview by Type 4
1.2.1 Drug-Coated Device 4
1.2.2 Prefilled Drug Delivery Systems 5
1.2.3 Nebulizer & Inhaler 7
1.2.4 Transdermal Delivery System 9
1.3 Global Drug-Device Combination Products Market Size by Type 10
1.3.1 Global Drug-Device Combination Products Market Size Overview by Type (2016-2027) 11
1.3.2 Global Drug-Device Combination Products Historic Market Size Review by Type (2016-2021) 12
1.3.3 Global Drug-Device Combination Products Forecasted Market Size by Type (2022-2027) 13
1.4 Key Regions Market Size Segment by Type 14
1.4.1 North America Drug-Device Combination Products Revenue Breakdown by Type (2016-2021) 14
1.4.2 Europe Drug-Device Combination Products Revenue Breakdown by Type (2016-2021) 15
1.4.3 Asia-Pacific Drug-Device Combination Products Revenue Breakdown by Type (2016-2021) 16
1.4.4 South America Drug-Device Combination Products Revenue Breakdown by Type (2016-2021) 17
1.4.5 Middle East and Africa Drug-Device Combination Products Revenue Breakdown by Type (2016-2021) 18
2 DRUG-DEVICE COMBINATION PRODUCTS MARKET COMPETITION BY COMPANY 20
2.1 Global Drug-Device Combination Products Market Size by Players (2019-2021) 20
2.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Drug-Device Combination Products as of 2020) 22
2.3 Founded Date of Key Drug-Device Combination Products Players 23
2.4 Global Top Players Drug-Device Combination Products Headquarters and Area Served 23
2.5 Key Players Drug-Device Combination Products Product Solution and Service 24
2.6 Competitive Status 25
2.6.1 Drug-Device Combination Products Market Concentration Rate 25
2.6.2 Mergers & Acquisitions, Expansion Plans 26
3 DRUG-DEVICE COMBINATION PRODUCTS STATUS AND OUTLOOK BY REGION 28
3.1 Global Drug-Device Combination Products Market Size Overview by Region 2016 VS 2021 VS 2027 28
3.2 Global Drug-Device Combination Products Market Size by Region (2016-2027) 29
3.3 Global Drug-Device Combination Products Historic Market Size by Region (2016-2021) 29
3.4 Global Drug-Device Combination Products Market Size Forecast by Region (2022-2027) 30
4 DRUG-DEVICE COMBINATION PRODUCTS MARKET OVERVIEW BY APPLICATION 32
4.1 Drug-Device Combination Products Market Segment by Application 32
4.1.1 Hospital & Clinic 32
4.1.2 Retail Pharmacies 33
4.2 Global Drug-Device Combination Products Market Size by Application 34
4.2.1 Global Drug-Device Combination Products Market Size Overview by Application (2016-2027) 34
4.2.2 Global Drug-Device Combination Products Historic Market Size by Application (2016-2021) 36
4.2.3 Global Drug-Device Combination Products Forecasted Market Size by Application (2022-2027) 36
4.3 Key Regions Market Size Segment by Application 37
4.3.1 North America Drug-Device Combination Products Revenue Breakdown by Application (2016-2021) 37
4.3.2 Europe Drug-Device Combination Products Revenue Breakdown by Application (2016-2021) 38
4.3.3 Asia-Pacific Drug-Device Combination Products Revenue Breakdown by Application (2016-2021) 39
4.3.4 South America Drug-Device Combination Products Revenue Breakdown by Application (2016-2021) 40
4.3.5 Middle East and Africa Drug-Device Combination Products Revenue Breakdown by Application (2016-2021) 41
5 NORTH AMERICA 43
5.1 North America Drug-Device Combination Products Market Size by Country (2016-2027) 43
5.2 United States 44
5.3 Canada 45
5.4 Mexico 45
6 EUROPE 46
6.1 Europe Drug-Device Combination Products Market Size by Country (2016-2027) 46
6.2 Germany 47
6.3 France 48
6.4 U.K. 48
6.5 Italy 49
6.6 Russia 49
6.7 Rest of Europe 50
7 ASIA-PACIFIC 51
7.1 Asia-Pacific Drug-Device Combination Products Market Size by Region (2016-2027) 51
7.2 China 53
7.3 Japan 53
7.4 South Korea 54
7.5 Southeast Asia 55
7.6 India 55
7.7 Australia 56
7.8 Rest of Asia-Pacific 56
8 SOUTH AMERICA 57
8.1 South America Drug-Device Combination Products Market Size by Country (2016-2027) 57
8.2 Brazil 58
8.3 Rest of South America 58
9 MIDDLE EAST & AFRICA 59
9.1 Middle East & Africa Drug-Device Combination Products Market Size by Country 59
9.2 Middle East 60
9.3 Africa 60
10 COMPANY PROFILES AND KEY FIGURES IN DRUG-DEVICE COMBINATION PRODUCTS BUSINESS 61
10.1 GSK 61
10.1.1 GSK Corporation Information 61
10.1.2 GSK Introduction and Business Overview 61
10.1.3 GSK Drug-Device Combination Products Revenue and Gross Margin (2019-2021) 62
10.1.4 GSK Drug-Device Combination Products Offered 62
10.1.5 GSK Recent Development 64
10.2 Novo Nordisk 64
10.2.1 Novo Nordisk Corporation Information 64
10.2.2 Novo Nordisk Introduction and Business Overview 65
10.2.3 Novo Nordisk Drug-Device Combination Products Revenue and Gross Margin (2019-2021) 65
10.2.4 Novo Nordisk Drug-Device Combination Products Offered 66
10.2.5 Novo Nordisk Recent Development 66
10.3 Eli Lilly 66
10.3.1 Eli Lilly Corporation Information 66
10.3.2 Eli Lilly Introduction and Business Overview 67
10.3.3 Eli Lilly Drug-Device Combination Products Revenue and Gross Margin (2019-2021) 67
10.3.4 Eli Lilly Drug-Device Combination Products Offered 67
10.3.5 Eli Lilly Recent Development 68
10.4 AstraZeneca 69
10.4.1 AstraZeneca Corporation Information 69
10.4.2 AstraZeneca Introduction and Business Overview 69
10.4.3 AstraZeneca Drug-Device Combination Products Revenue and Gross Margin (2019-2021) 69
10.4.4 AstraZeneca Drug-Device Combination Products Offered 70
10.4.5 AstraZeneca Recent Development 71
10.5 Sanofi 71
10.5.1 Sanofi Corporation Information 71
10.5.2 Sanofi Introduction and Business Overview 72
10.5.3 Sanofi Drug-Device Combination Products Revenue and Gross Margin (2019-2021) 72
10.5.4 Sanofi Drug-Device Combination Products Offered 72
10.5.5 Sanofi Recent Development 73
10.6 Boston Scientific 73
10.6.1 Boston Scientific Corporation Information 73
10.6.2 Boston Scientific Introduction and Business Overview 74
10.6.3 Boston Scientific Drug-Device Combination Products Revenue and Gross Margin (2019-2021) 74
10.6.4 Boston Scientific Drug-Device Combination Products Offered 75
10.6.5 Boston Scientific Recent Development 76
10.7 Abbott 76
10.7.1 Abbott Corporation Information 76
10.7.2 Abbott Introduction and Business Overview 77
10.7.3 Abbott Drug-Device Combination Products Revenue and Gross Margin (2019-2021) 77
10.7.4 Abbott Drug-Device Combination Products Offered 77
10.8 Boehringer Ingelheim 78
10.8.1 Boehringer Ingelheim Corporation Information 78
10.8.2 Boehringer Ingelheim Introduction and Business Overview 79
10.8.3 Boehringer Ingelheim Drug-Device Combination Products Revenue and Gross Margin (2019-2021) 79
10.8.4 Boehringer Ingelheim Drug-Device Combination Products Offered 79
10.8.5 Boehringer Ingelheim Recent Development 80
10.9 Medtronic 81
10.9.1 Medtronic Corporation Information 81
10.9.2 Medtronic Introduction and Business Overview 81
10.9.3 Medtronic Drug-Device Combination Products Revenue and Gross Margin (2019-2021) 82
10.9.4 Medtronic Drug-Device Combination Products Offered 82
10.9.5 Medtronic Recent Development 83
10.10 Mylan 83
10.10.1 Mylan Corporation Information 83
10.10.2 Mylan Introduction and Business Overview 84
10.10.3 Mylan Drug-Device Combination Products Revenue and Gross Margin (2019-2021) 84
10.10.4 Mylan Drug-Device Combination Products Offered 85
10.10.5 Mylan Recent Development 86
10.11 3M 86
10.11.1 3M Corporation Information 86
10.11.2 3M Introduction and Business Overview 86
10.11.3 3M Drug-Device Combination Products Revenue and Gross Margin (2019-2021) 87
10.11.4 3M Drug-Device Combination Products Offered 87
10.12 Hisamitsu 88
10.12.1 Hisamitsu Corporation Information 88
10.12.2 Hisamitsu Introduction and Business Overview 89
10.12.3 Hisamitsu Drug-Device Combination Products Revenue and Gross Margin (2019-2021) 89
10.12.4 Hisamitsu Drug-Device Combination Products Offered 90
10.13 Smith & Nephew 90
10.13.1 Smith & Nephew Corporation Information 90
10.13.2 Smith & Nephew Introduction and Business Overview 91
10.13.3 Smith & Nephew Drug-Device Combination Products Revenue and Gross Margin (2019-2021) 91
10.13.4 Smith & Nephew Drug-Device Combination Products Offered 91
10.13.5 Smith & Nephew Recent Development 93
10.14 Molnlycke 93
10.14.1 Molnlycke Corporation Information 93
10.14.2 Molnlycke Introduction and Business Overview 93
10.14.3 Molnlycke Drug-Device Combination Products Revenue and Gross Margin (2019-2021) 94
10.14.4 Molnlycke Drug-Device Combination Products Offered 94
10.15 Teleflex 95
10.15.1 Teleflex Corporation Information 95
10.15.2 Teleflex Introduction and Business Overview 95
10.15.3 Teleflex Drug-Device Combination Products Revenue and Gross Margin (2019-2021) 96
10.15.4 Teleflex Drug-Device Combination Products Offered 96
10.15.5 Teleflex Recent Development 97
10.16 BD 97
10.16.1 BD Corporation Information 97
10.16.2 BD Introduction and Business Overview 97
10.16.3 BD Drug-Device Combination Products Revenue and Gross Margin (2019-2021) 98
10.16.4 BD Drug-Device Combination Products Offered 98
10.17 Lepu Medical 99
10.17.1 Lepu Medical Corporation Information 99
10.17.2 Lepu Medical Introduction and Business Overview 99
10.17.3 Lepu Medical Drug-Device Combination Products Revenue and Gross Margin (2019-2021) 100
10.17.4 Lepu Medical Drug-Device Combination Products Offered 100
10.18 MicroPort 102
10.18.1 MicroPort Corporation Information 102
10.18.2 MicroPort Introduction and Business Overview 102
10.18.3 MicroPort Drug-Device Combination Products Revenue and Gross Margin (2019-2021) 103
10.18.4 MicroPort Drug-Device Combination Products Offered 103
10.19 Terumo 104
10.19.1 Terumo Corporation Information 104
10.19.2 Terumo Introduction and Business Overview 105
10.19.3 Terumo Drug-Device Combination Products Revenue and Gross Margin (2019-2021) 105
10.19.4 Terumo Drug-Device Combination Products Offered 105
10.20 B. Braun 106
10.20.1 B. Braun Corporation Information 106
10.20.2 B. Braun Introduction and Business Overview 107
10.20.3 B. Braun Drug-Device Combination Products Revenue and Gross Margin (2019-2021) 107
10.20.4 B. Braun Drug-Device Combination Products Offered 107
10.21 Antares Pharma 109
10.21.1 Antares Pharma Corporation Information 109
10.21.2 Antares Pharma Introduction and Business Overview 110
10.21.3 Antares Pharma Drug-Device Combination Products Revenue and Gross Margin (2019-2021) 110
10.21.4 Antares Pharma Drug-Device Combination Products Offered 110
11 UPSTREAM, OPPORTUNITIES, CHALLENGES, RISKS AND INFLUENCES FACTORS ANALYSIS 112
11.1 Drug-Device Combination Products Key Raw Materials 112
11.1.1 Key Raw Materials 112
11.1.2 Key Raw Materials Market Concentration Rate 112
11.1.3 Raw Materials Key Suppliers 112
11.2 Manufacturing Cost Structure 113
11.2.1 Raw Materials 113
11.2.2 Labor Cost 113
11.2.3 Manufacturing Expenses 113
11.3 Drug-Device Combination Products Industrial Chain Analysis 114
11.4 Drug-Device Combination Products Market Dynamics 114
11.4.1 Drug-Device Combination Products Industry Trends 114
11.4.2 Drug-Device Combination Products Market Drivers 115
11.4.3 Drug-Device Combination Products Market Challenges 116
11.4.4 Drug-Device Combination Products Market Restraints 116
12 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS 117
12.1 Sales Channel 117
12.2 Drug-Device Combination Products Distributors 118
12.3 Drug-Device Combination Products Downstream Customers 119
13 RESEARCH FINDING/CONCLUSION 122
14 METHODOLOGY AND DATA SOURCE 124
14.1 Methodology/Research Approach 124
14.1.1 Research Programs/Design 124
14.1.2 Market Size Estimation 125
14.1.3 Market Breakdown and Data Triangulation 126
14.2 Data Source 127
14.2.1 Secondary Sources 127
14.2.2 Primary Sources 128
14.3 Disclaimer 129
14.4 Author List 130